PE’s $10bn India hospital push faces growing affordability backlash

Private equity firms have invested approximately $10 billion in Indian hospital operators over the last five years, a move that has significantly fueled expansion and consolidation within the country's healthcare market. This substantial capital inflow, however, is now attracting scrutiny due to concerns about rising treatment costs and the subsequent financial burden placed on patients and insurance providers, according to a Bloomberg report. The investment has helped hospital groups across India fund new facilities, technology, and acquisitions. While PE-backed operators currently account for less than five percent of the nation's hospital beds, they have established notable positions in high-value specialties such as oncology and cardiac care. This trend has been driven by India's expanding healthcare infrastructure needs.

The highly fragmented nature of the Indian hospital sector has also presented opportunities for private equity sponsors to create larger, more integrated networks through strategic acquisitions. Firms such as Blackstone, KKR, TPG, and General Atlantic are among the international investors contributing to this market growth.

This strategy has yielded strong financial returns for some investors. For example, KKR's involvement with Kerala-based Baby Memorial Hospital has been followed by rapid expansion and further acquisitions. KKR also agreed to acquire Medicover's Indian operations for $1.4 billion, which will substantially grow its hospital footprint in southern India. The firm previously supported Radiant Life Care and its merger with Max Healthcare Institute, with its 2022 exit from Max generating considerable returns. Other investors have similarly benefited from India’s increasingly liquid capital markets, utilizing stock-market listings and secondary transactions for exits.

Temasek, for instance, reportedly achieved an estimated tenfold return on its investment in Manipal Health Enterprises following a partial sale related to the hospital operator's IPO, yielding an internal rate of return of approximately 30%. The sector's robust performance is expected to continue, with Crisil projecting private hospital revenues to increase by as much as 15% in fiscal year 2027, driven by higher patient volumes and increased revenue per occupied bed. This continued growth has encouraged further investment, reinforcing the private equity sector's strong belief in the Indian healthcare market's potential.

However, these financial gains have intensified the debate surrounding healthcare affordability. A parliamentary committee has voiced concerns that unchecked foreign capital could accelerate consolidation among large hospital groups. It has recommended tighter scrutiny of foreign investment, potential price controls, and the establishment of an independent hospital regulator. Medical inflation has been as high as 13% annually, and treatment at private hospitals can be several times more expensive than in public facilities, particularly for treatments like cancer, cardiac care, and maternity services. This has led to a growing divide between insurers and hospitals over cost responsibility.

For private equity investors, this affordability debate poses a significant challenge to an investment model that relies on expanding hospital networks, enhancing operational efficiency, and ultimately realizing gains through strategic sales or public listings. Industry executives have cautioned that aggressive regulatory intervention in healthcare pricing could deter further international investment in India. This suggests that the sector may face increased regulatory oversight and a potential re-evaluation of investment strategies to balance profitability with public affordability concerns, which could shape the future landscape of PE involvement in Indian healthcare.